Story
Capricor Therapeutics Stock Rallies as FDA Extends Review for DMD Drug

Shares of Capricor Therapeutics (NASDAQ: CAPR) rose sharply in pre-market trading after the U.S. Food and Drug Administration (FDA) extended its review period for the company's Duchenne muscular dystrophy (DMD) treatment, deramiocel. The decision pushes the target action date back by three months, a development that investors are viewing as constructive for the drug's approval pathway.
FDA Extends Review, Avoiding Rejection
The FDA has set a new Prescription Drug User Fee Act (PDUFA) target action date of November 22, 2026, delayed from the original date of August 22, 2026. The extension was prompted by Capricor's submission of an amendment to its Biologics License Application (BLA), which included new 24-month data from its pivotal Phase 3 HOPE-3 study.
Critically for investors, the agency did not issue a Complete Response Letter (CRL), which would have effectively rejected the application and likely required new clinical trials. The FDA's willingness to take additional time to review the new long-term data is being interpreted as a sign that the application remains under active and serious consideration.
Market and Analyst Reaction
The market reacted positively to the news, with Capricor's stock climbing 6.9% in pre-open trading and extending a rally from the prior session. The move signals investor relief that the company avoided the significant setback of a CRL.
AdAnalyst sentiment has also grown more positive, underpinning the rally. Following the news, Oppenheimer upgraded CAPR shares to Outperform from Perform. This follows a recent upgrade from Cantor Fitzgerald, which raised its rating to Overweight and increased its price target to $28 from $3.50.
Context and Outlook
Deramiocel is an investigational cell therapy for the treatment of Duchenne muscular dystrophy, a rare genetic disorder causing progressive muscle weakness. The amended application includes analyses supporting a refined indication focused on upper limb function, which was the primary endpoint of the HOPE-3 trial.
The stock's volatile 52-week range of $2.96 to $40.37 underscores the high-risk, high-reward nature of clinical-stage biotechnology companies awaiting pivotal regulatory decisions. The rally was highly company-specific, significantly outpacing modest gains in the broader market indices.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.